ArticleScientific reports2026
Intravenous transplantation of multi-lineage differentiating stress enduring cell promotes functional recovery after traumatic brain injury in mice.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Multilineage-differentiating stress-enduring (Muse) cells are a unique subset of endogenous stem cells that are non-tumorigenic and possess pluripotent-like traits with macrophage-like functions. These cells are naturally present in bone marrow, peripheral blood, connective tissues of various organs, and the umbilical cord. Muse cells are defined by their expression of stage-specific embryonic antigen-3 (SSEA-3) and their high tolerance to cellular stress such as ischemia, oxidative injury, and inflammation. This study aimed to explore the therapeutic effects of intravenous administration of Muse cells on functional recovery after traumatic brain injury (TBI). Mouse TBI model was produced by applying a 3.5-mm-diameter copper cylinder cooled with liquid nitrogen to the right parietal bone. At 7 days after TBI, the animals randomly received an injection of either 6.0×104 human Muse cells (Muse group), 6.0×104 human mesenchymal stromal cells (low-dose MSC group), 1.6×106 human MSCs (high-dose MSC group), or PBS (vehicle group) through the tail vein (n=10 in each group). Motor function was assessed using a rotarod and cylinder test for 84 days after TBI. Subsequently, histological analysis was performed to explore the engraftment and phenotypic fate of Muse cells in the brain. Functional recovery was significantly enhanced on both rotarod and cylinder tests at 28 days and 42 days after TBI in Muse group, respectively, but not in vehicle group and low-dose MSCs group. Only limited effect was observed on cylinder test at 84 days after TBI in high-dose MSCs. Human mitochondria-positive cells were densely engrafted in the peri-TBI area in Muse group, but their number was very few in low- and high-dose MSC groups. About 60% and 20% of Muse cells were positive for NeuN and GSTpi, respectively. The findings strongly suggest that intravenously administered Muse cells aggressively migrate towards the injured brain, express specific markers for neurons and oligodendrocytes, and enhance the recovery of motor function in mice TBI model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.